Drug survival of systemic and biological treatments for moderate-to-severe atopic dermatitis in adults: a multicentre retrospective observational study

Abstract

This study provides a comparative survival analysis among most treatments available for moderate-to-severe AD. Regarding systemic drug survival, our findings are in reasonable agreement with previous studies. Considering survival analysis as a reflection of the performance of a drug in daily practice, the results for dupilumab in our study demonstrate a clear superiority in terms of persistence compared with systemic therapy. The dropout rate for the dupilumab group was only 6% in 20 months, whereas it was above 65% for all the other drugs under study. A limitation of this study is the retrospective design, which is dependent on the quality of the medical records.